Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.
The abbreviations in the column Type are as follows: mab: whole monoclonal antibody Fab: fragment, antigen-binding (one arm) F(ab')2: fragment, antigen-binding, including hinge region (both arms) Fab': fragment, antigen-binding, including hinge region (one arm) Variable fragments: scFv: single-chain variable fragment di-scFv: dimeric single-chain variable fragment sdAb: single-domain antibody BsAb: bispecific monoclonal antibody: 3funct: trifunctional antibody BiTE: bi-specific T-cell engager
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Name Brand name Type Source Target Approved Use 3F8 mab mouse GD2 ganglioside neuroblastoma Abagovomab mab mouse CA-125 (imitation) ovarian cancer Abciximab ReoPro Fab chimeric CD41 (integrin alpha-IIb) Y platelet aggregation inhibitor Abituzumab mab humanized CD51 cancer Abrezekimab Fab humanized IL-13 Abrilumab mab human integrin α4 β7 inflammatory bowel disease, ulcerative colitis, Crohn's disease Actoxumab mab human Clostridioides difficile Clostridioides difficile colitis Adalimumab Humira mab human TNF-α Y rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hemolytic disease of the newborn hidradentis suppuraatva Adecatumumab mab human EpCAM prostate and breast cancer Aducanumab Aduhelm mab human Amyloid beta Y Alzheimer's disease Afasevikumab mab human IL-17A, IL-17F multiple sclerosis Afelimomab F(ab')2 mouse TNF-α sepsis Alacizumab pegol F(ab')2 humanized VEGFR2 cancer Alemtuzumab Lemtrada, Campath mab humanized CD52 Y multiple sclerosis Alirocumab Praluent mab human PCSK9 Y hypercholesterolemia Altumomab pentetate Hybri-ceaker mab mouse Carcinoembryonic antigen (CEA) colorectal cancer (diagnosis) Amatuximab mab chimeric mesothelin cancer Amivantamab Rybrevant BsAb human Epidermal growth factor receptor (EGFR), cMet Y non-small cell lung cancer Anatumomab mafenatox Fab mouse Tumor-associated glycoprotein 72 (TAG-72) non-small cell lung cancer Andecaliximab mab chimeric gelatinase B gastric cancer or gastroesophageal junction adenocarcinoma Anetumab ravtansine mab human mesothelin (MSLN) cancer Anifrolumab Saphnelo mab human IFN-α/β receptor Y systemic lupus erythematosus Ansuvimab Ebanga mab human Ebola virus glycoprotein Y treatment of Zaire ebolavirus (Ebola virus) Anrukinzumab(= IMA-638) mab humanized IL-13 asthma Apitegromab Isembyld mab human proforms of myostatin Y Spinal muscular atrophy Apolizumab mab humanized HLA-DR hematological cancers Aprutumab ixadotin mab human FGFR2 Arcitumomab CEA-Scan Fab' mouse Carcinoembryonic antigen (CEA) gastrointestinal cancers (diagnosis) Ascrinvacumab mab human activin receptor-like kinase 1 cancer Aselizumab mab humanized L-selectin (CD62L) severely injured patients Atezolizumab Tecentriq mab humanized PD-L1 Y cancer Atidortoxumab mab human Staphylococcus aureus alpha toxin Atinumab mab human RTN4 Atoltivimab mab human Ebola virus glycoprotein part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus) Atoltivimab/maftivimab/odesivimab Inmazeb mab human Y treatment of Zaire ebolavirus (Ebola virus) Atorolimumab mab human Rhesus factor hemolytic disease of the newborn Avelumab Bavencio mab human PD-L1 Y cancer Axatilimab Niktimvo mab humanized CSF1R Y chronic graft-versus-host disease Azintuxizumab vedotin mab chimeric/humanized CD319 cancer Bamlanivimab mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 US emergency use authorization (EUA) when used with etesevimab COVID-19 Bapineuzumab mab humanized β-amyloid Alzheimer's disease Basiliximab Simulect mab chimeric CD25 (α chain of IL-2 receptor) Y prevention of organ transplant rejections Bavituximab mab chimeric phosphatidylserine cancer, viral infections BCD-100 human PD-1 melanoma Bebtelovimab mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 US emergency use authorization (EUA) COVID-19 Bectumomab LymphoScan Fab' mouse CD22 non-Hodgkin's lymphoma (detection) Bedinvetmab Librela mab veterinary nerve growth factor (NGF) Y pain associated with osteoarthritis in dogs Begelomab mab mouse DPP4 Belantamab mafodotin Blenrep mab humanized B-cell maturation antigen (BCMA) Y (Withdrawn) relapsed or refractory multiple myeloma Belimumab Benlysta mab human B-cell activating factor (BAFF) Y systemic lupus erythematosus without renal or CNS involvement Bemarituzumab mab humanized FGFR2 gastric cancer or gastroesophageal junction adenocarcinoma Benralizumab Fasenra mab humanized CD125 Y asthma Berlimatoxumab mab human Staphylococcus aureus bi-component leukocidin Bermekimab Xilonix mab human IL-1α colorectal cancer Bersanlimab mab human ICAM-1 Bertilimumab mab human CCL11 (eotaxin-1) severe allergic disorders Besilesomab Scintimun mab mouse Carcinoembryonic antigen (CEA)-related antigen inflammatory lesions and metastases (detection) Bevacizumab Avastin mab humanized VEGF-A Y metastatic cancer, retinopathy of prematurity Bezlotoxumab Zinplava mab human Clostridioides difficile Y Clostridioides difficile colitis Biciromab FibriScint Fab' mouse fibrin II, beta chain thromboembolism (diagnosis) Bimagrumab mab human ACVR2B myostatin inhibitor Bimekizumab Bimzelx mab humanized IL-17A, IL-17F, IL-17AF Y psoriasis Birtamimab mab chimeric serum amyloid A protein amyloidosis Bivatuzumab mab humanized CD44 v6 squamous cell carcinoma Bleselumab mab human CD40 organ transplant rejection Blinatumomab Blincyto BiTE mouse CD19 Y pre-B Acute lymphoblastic leukemia (ALL) (CD19+) Blontuvetmab Blontress mab veterinary CD20 Blosozumab mab humanized SOST osteoporosis Bococizumab mab humanized PCSK9 dyslipidemia Brazikumab mab human IL-23 Crohn's disease Brentuximab vedotin Adcentris mab chimeric CD30 (TNFRSF8) Y Hodgkin's lymphoma, anaplastic large-cell lymphoma Briakinumab mab human IL-12, IL-23 psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis Brodalumab Siliq mab human IL-17 Y Plaque psoriasis Brolucizumab Beovu scFv humanized vascular endothelial growth factor A (VEGFA) Y wet age-related macular degeneration Brontictuzumab mab humanized Notch 1 cancer Burosumab Crysvita mab human FGF 23 Y X-linked hypophosphatemia Cabiralizumab mab humanized CSF1R metastatic pancreatic cancer Camidanlumab tesirine mab human CD25 (α chain of IL-2 receptor) B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia Camrelizumab mab humanized PD-1 hepatocellular carcinoma Canakinumab Ilaris mab human IL-1 Y cryopyrin-associated periodic syndrome, Yao Syndrome, Adult Onset Still's Disease Cantuzumab mertansine mab humanized CanAg (a glycoform of MUC1) colorectal cancer etc. Cantuzumab ravtansine mab humanized CanAg (a glycoform of MUC1) cancers Caplacizumab Cablivi sdAb humanized VWF Y thrombotic thrombocytopenic purpura, thrombosis Capromab Prostascint mab mouse Glutamate carboxypeptidase II Y prostate cancer (detection) Carlumab mab human MCP-1 oncology/immune indications Carotuximab mab chimeric endoglin angiosarcoma Catumaxomab Removab 3funct rat/mouse hybrid EpCAM, CD3 Y ovarian cancer, malignant ascites, gastric cancer cBR96-doxorubicin immunoconjugate mab humanized Lewis-Y antigen cancer Casirivimab mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Yes when used with imdevimab COVID-19 Cedelizumab mab humanized CD4 prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab Libtayo mab human PD-1 Y cutaneous squamous cell carcinoma Cergutuzumab amunaleukin mab humanized IL-2 cancer Certolizumab pegol Cimzia Fab' humanized TNF-α Y Crohn's disease, rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis Cetrelimab mab human PD-1 cancer Cetuximab Erbitux mab chimeric Epidermal growth factor receptor (EGFR) Y metastatic colorectal cancer and head and neck cancer Cetuximab beta Enlituo mab Y Cibisatamab mab humanized CEACAM5 cancer Cilgavimab mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 US emergency use authorization (EUA) when used with tixagevimab COVID-19 Cirmtuzumab humanized ROR1 chronic lymphocytic leukemia Citatuzumab bogatox Fab humanized EpCAM ovarian cancer and other solid tumors Cixutumumab mab human IGF-1 receptor (CD221) solid tumors Clazakizumab mab humanized IL-6 rheumatoid arthritis Clenoliximab mab chimeric CD4 rheumatoid arthritis Clesrovimab Enflonsia mab human respiratory syncytial virus F protein Y respiratory syncytial virus (prevention) Clivatuzumab tetraxetan hPAM4-Cide mab humanized MUC1 pancreatic cancer Codrituzumab mab humanized glypican 3 cancer Cofetuzumab pelidotin mab humanized PTK7 cancer Coltuximab ravtansine mab chimeric CD19 cancer Conatumumab mab human TRAIL-R2 cancer Concizumab Alhemo mab humanized tissue factor pathway inhibitor (TFPI) Y bleeding with hemophilia Cosfroviximab ZMapp mab chimeric ebolavirus glycoprotein Ebola virus Cosibelimab Unloxcyt mab human Programmed death ligand-1 (PD-L1) Y cutaneous squamous cell carcinoma Crenezumab mab humanized β-amyloid (1-40 and 1-42) Alzheimer's disease Crizanlizumab Adakveo mab humanized selectin P Y sickle-cell disease Crotedumab mab human glucagon receptor (GCGR) diabetes Crovalimab Piasky mab humanized C5 Y paroxysmal nocturnal hemoglobinuria CR6261 mab human Hemagglutinin (influenza) infectious disease/influenza A Cusatuzumab mab humanized CD70 cancer Dacetuzumab mab humanized CD40 hematologic cancers Daclizumab Zenapax mab humanized CD25 (α chain of IL-2 receptor) Y prevention of organ transplant rejections, multiple sclerosis Dalotuzumab mab humanized IGF-1 receptor (CD221) cancer etc. Dapirolizumab pegol mab humanized CD154 (CD40L) Daratumumab Darzalex mab human CD38 Y multiple myeloma Dectrekumab mab human IL-13 Demcizumab mab humanized DLL4 cancer Denintuzumab mafodotin mab humanized CD19 cancer Denosumab Prolia mab human RANKL Y osteoporosis, bone metastases etc. Depatuxizumab mafodotin mab chimeric/humanized EGFR glioblastoma Depemokimab Exdensur mab humanized IL-5 Y asthma Derlotuximab biotin mab chimeric histone complex recurrent glioblastoma multiforme Detumomab mab mouse B-lymphoma cell lymphoma Dezamizumab mab humanized serum amyloid P component Dinutuximab Unituxin mab chimeric GD2 ganglioside Y neuroblastoma Dinutuximab beta Qarziba mab chimeric GD2 ganglioside Y neuroblastoma Diridavumab mab human Hemagglutinin (influenza) influenza A Divozilimab Ivlizi mab humanized CD20 Y (Russia) multiple sclerosis Domagrozumab mab humanized GDF-8 Duchenne muscular dystrophy Donanemab Kisunla mab humanized Amyloid beta Y Alzheimer's disease Dorlimomab aritox F(ab')2 mouse Dostarlimab Jemperli mab humanized PCDP1 Y endometrial cancer Drozitumab mab human DR5 cancer etc. DS-8201 humanized HER2 gastric or gastroesophageal junction adenocarcinoma Duligotuzumab mab humanized ERBB3 (HER3) testicular cancer Dupilumab Dupixent mab human IL-4Rα Y atopic dermatitis, asthma, nasal polyps Durvalumab Imfinzi mab human PD-L1 Y cancer Dusigitumab mab human IGF-2 B-cell malignancies Duvortuxizumab scFv chimeric/humanized CD19, CD3E cancer Ecromeximab mab chimeric GD3 ganglioside malignant melanoma